Preclinical studies of ApoA-I Milano demonstrate reduced Aβ plaque deposition in Alzheimer’s disease models, suggesting potential disease-modifying effects [171]. This evidence concerns the gene APOA1 and early-onset autosomal dominant Alzheimer disease.